|
Developed by 
|
Supported by 
|
Glecaprevir Pibrentasvir LA injection
Developer(s)
|
Tandem Nano Originator
https://www.liverpool.ac.uk/collaborate/enterprise/spin-out-companies/tandem-nano/
United Kingdom |
Drug structure
Placeholder for LAI GP
CELT
Glecaprevir and Pibrentasvir Chemical Structures
Drugbank
Drug information
Associated long-acting platforms
Aqueous drug particle suspension
Administration route
Subcutaneous, Intramuscular, Route of administration of the injectable formulation is being determined in the clinical program
Therapeutic area(s)
HCV
Use case(s)
Treatment
Use of drug
Ease of administration
Administered by a community health worker
Administered by a nurse
Administered by a specialty health worker
To be determined
Frequency of administration
Other/Variable/Unknown : To be determined based on clinical development
Once
User acceptance
To be determined
Dosage
Available dose and strength
Not provided
Maximum dose
Not provided
Recommended dosing regimen
Not provided
Additional comments
Not provided
Dosage link(s)
Not provided